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Accepted 17 July 2019Fribrodysplasia ossiﬁcans progressiva (FOP) is a rare genetic disease characterized by progressive heterotopic os-
siﬁcation of connective tissues, episodic ﬂare-ups and bilateral deformities of the great toe (hallux valgus). As
faulty tissue repair processes progressively calcify tissue, patients suffer from swelling and limited mobility in
that area. We present a case of a 66-year-old woman who had initially presented at age 54 without the hallux
valgus deformity or classic-type ﬂare-ups. As there is currently no cure for FOP,management ismainly symptom
control. Physicians should still consider FOP if imaging indicates progressive heterotopic ossiﬁcation in the ab-
sence of hallux valgus in an older patient.
© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In heterotopic ossiﬁcation (HO) ectopic bone tissue develops inside
muscle or other soft tissues such as tendons, ligaments, subcutaneous
fats, and nerves [1,2]. While the pathophysiology of HO is questionable,
it appears to be caused bymalfunctioning tissue repair processes [1]. HO
is divided into nonhereditary and hereditary forms. The nonhereditary
traumatic subtype is a result of soft-tissue injury from traumaor surgery
and the most common form of HO [2]. This case report focuses on the
hereditary subtype ﬁbrodysplasia ossiﬁcans progressiva (FOP), which
is also known as myositis ossiﬁcans progressiva (MOP), Munchmeyer's
disease, or “stoneman disease” [3]. Importantly, the hereditary forms of
HO differ signiﬁcantly from the nonhereditary forms in presentation
and clinical consequences [1].
FOP is characterized by skeletal malformations of the phalanges,
metacarpals and spine with HO at extra-skeletal sites due to calciﬁed
edema [4–6]. Patients with FOP can experience extreme limitations in
mobility [6]. The ﬁrst case was reported by Patin in 1692 and Freke
later deﬁned the symptoms of FOP in 1739. Stonham, Burton-Fanning,
and other clinicians recorded further cases of FOP with different gen-
ders, ages, and hereditary forms [7]. It has a prevalence of 1 in
2,000,000, unaffected by ethnicity, sex, or geographic location [5,7].va; HO,Heterotopic ossiﬁcation.
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dit@leeds.ac.uk (H. Pandit).FOP is autosomal dominantwithmost cases being sporadic, present-
ing between birth to 10 years, and slowly progressing to become fatal at
age 40 on average due to thoracic insufﬁciency syndrome [5–7].
The goal of this report is to introduce an atypical case of
ﬁbrodysplasia ossiﬁcans progressiva (FOP) that presentedwith nonclas-
sical ﬂare-ups, without the hallux valgus deformity, and later in life.
2. Case Report
A 66-year-old woman presented to the outpatient center for the De-
partment of Orthopaedics with severe hip and knee stiffness. Associated
pain was particularly worse after exertion. For multiple days she was
bed-bound due to pain, stiffness, and fatigue affecting her lower limbs
bilaterally.
At age 54 the patient ﬁrst reported complaints of ongoing stiffness
and discomfort affecting her legs. Due to the extremely late onset and
absence of the classic hallux valgus deformity, the diagnosis of FOP
eluded clinicians for many years. Electromyography (EMG) done
showed diffuse myopathy in the lower limbs. Early diagnoses included
polyarthralgia, ﬁbromyalgia, lupus, and Ehlers-Danlos syndrome. The
most deﬁnitive diagnosis reached during these years was advanced-
stage muscle disease or a connective-tissue disease process.
Clinical exam conﬁrmed stiff hips and knees, but the stiffness was
primarily in the soft tissues and not the joints. There was a 40° bilateral
ﬂexion deformity of the knees, with the right being more severe. While
less pronounced than in the lower limbs, there was also stiffness in the
upper limbs. Shoulder ﬂexion was restricted to 40°, abduction to 50°,
and rotation to 5°. There was limited range of ﬂexion and extension in
her spine as well. Small-joint effusion was present.
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since age 13, Von Willebrand disease, hepatitis B and C, and Raynaud's
phenomena.
Unremitting stiffness had progressed over the years. Pethidine in
oral tablet form had been one of the few analgesics the patient had
responded to and could tolerate. At presentation the patient was on
low-dose corticosteroids to manage inﬂammation.
Ultimately, a clinical diagnosis of atypical myositis ossiﬁcans
progressiva was reached due to progressive stiffness complemented
by imaging indicating soft-tissue calciﬁcations seen bilaterally within
the appendicular musculature (Fig. 1).
3. Discussion
FOP is a severe and disabling condition as it is irreversible, wide-
spread, and progressive [5]. As the HO arises in the connective tissue
in muscles, fascia, ligaments, and joint capsules instead of the actual
muscle ﬁbers, the term ﬁbrodysplasia ossiﬁcans progressiva (FOP) is fa-
vored over myositis ossiﬁcans progressiva (MOP) [3].
3.1. Mechanism
The molecular mechanisms of pathogenesis are not completely un-
derstood, but multiple studies show a link between the upregulation
of the bone morphogenetic protein (BMP) signaling pathway and FOP
[8]. BMP ligands in the TGF-β family bind type II receptors, such as
BMP receptor type II (BMPR-II), activin receptor type IIA (ActR-IIA) or
activin receptor type IIB (ActR-IIB), which then recruit a type I receptor,
activin type IA/activin-like kinase 2 (ACVR1/ALK2), in the cell mem-
brane [5]. The type II receptors are constitutively active Ser/Thr kinases
that phosphorylate a GS (glycine-serine) domain on the type I ACVR1/
ALK2 receptor. An activated ACVR1/ALK2 receptor phosphorylates
downstream cytoplasmic substrates in the Smad signaling family,
which can subsequently modify gene expression in the nucleus [4,5].
The mutated ACVR1/ALK2 type II receptor linked to FOP has a GS do-
main that is hypersensitive to phosphorylation by type II receptors. If
the GS domain is mutated, the inhibitory protein, FKBP12, is unable to
bind to prevent constitutive activation of the type 1 receptor in absence
of a ligand [6]. This causes constitutive BMP signaling and implies a
gain-of-function mutation [4].
3.2. Clinical Presentation
The common clinical features that deﬁne FOP are progressive HO in
soft tissues and congenital malformations of the great toes (hallux val-
gus) [5]. While deformity of the great toe appears at birth in 80% ofFig. 1. X-ray showing bilateral heterotopic ossiﬁcation of the thigh muscles.patients with FOP, our patient didoes not have this [3,4]. The HO in
FOP normally presents between birth and 26 years of age, with presen-
tation in the ﬁrst decade being the most common. There are a few case
reports of patients presentingwith FOP in their late forties, but age 54 is
the oldest presentation reported in the literature to date [9]. Although
the rate of HO can vary in FOP patients, our patient's ossiﬁcation had
progressed along a normal time course [5]. The stiffness had intensiﬁed
over a decade, to the point where the patient had to walk with a shuf-
ﬂing gait. The HO had presented primarily in the hips and shoulders.
This is consistent with the anatomic pattern in classic FOP patients,
where the axial and proximal regions of the appendicular skeleton are
affected before the distal regions [5]. Patients with FOP usually suffer
from recurrent episodes, termed ﬂare-ups, which are deﬁned by soft-
tissue swellings that are inﬂammatory and painful [5]. These ﬂare-ups
are an endochondral process transforming connective tissues into rib-
bons or sheets of heterotopic bone that can cross joints, causing limited
mobility [3]. Our patient did appear to undergo the usual ﬂare-ups, but
had ﬂu-like symptoms and widespread feelings of stiffness throughout
the body. She had been diagnosed with hemiplegic migraines since
age 13. Recurrent headaches are not associated with FOP, but many
patients with FOP do report having them, and females with FOP
are four times more likely to report recurrent headaches than males
with FOP [10].
3.3. Radiographic Features
Often the typical presentation of soft-tissue lesions and the bilateral
hallux valgus deformity allow for the clinical diagnosis of FOP, rendering
radiographs unnecessary [6]. However, as the great toe deformity was
absent in our patient, diagnosis by imaging became more pertinent.
Recent radiographs of the hips and shoulders showed bilateral densely
calciﬁed soft-tissue masses that had progressed over the years,
indicative of FOP [2].
3.4. Diagnosis
Clinicians oftenmisdiagnose FOPas aggressive juvenileﬁbromatosis,
lymphedema, bursitis, or soft-tissue sarcoma, as it is challenging to re-
late ﬂare-ups on the head, neck, and back with the bilateral congenital
deformity of the great toes [6,7]. This can lead to incorrect treatments
(e.g. biopsies), which can worsen the symptoms of the disease [3]. The
most deﬁnitive way to diagnose FOP is through genetic analysis of the
ACV1/ALK2 gene mutation. Over 90% of individuals with the classic
form of FOP have the same mutation (c.617GNA; R206H) in the GS do-
main, while patients with an atypical presentation have a different mu-
tation, but still in the GS domain of the ACVR1/ALK2 gene [4].
3.5. Treatment
There is currently no cure for FOP. Management is aimed at symp-
tom control and the prevention of ﬂare-ups, which can be provoked
by surgery, trauma, viral infections, intramuscular injections, muscle
strain, and fatigue [6]. Administration of glucocorticoids at the onset of
a ﬂare-up can manage inﬂammation and tissue edema in the appendic-
ular skeleton. Ongoing ﬂare-ups and chronic pain can be treated with
nonsteroidal anti-inﬂammatory drugs (NSAIDs), mast cell stabilizers,
leukotriene inhibitors, and cyclo-oxygenase-2-inhibitors. Ascorbic
acid can control the rate of progression of ossiﬁcation, probably by
altering the synthesis of procollagen type III during the inﬂammatory
periods [3].
With the discovery that the ACVR1/ALK2mutation promotes upreg-
ulation of theBMP signalingpathway in the absence of ligand, leading to
HO, developing drugs to inhibit these processes is under current inves-
tigation [7]. Proposed strategies include ALK2 protein inhibitors, osteo-
blastic progenitor cell activity inhibitors, compounds that inhibit the
Ser/Thr kinase activity of ALK2, andRNAi techniques that inhibitmutant
3C.M. Cunningham et al. / Case Reports in Women's Health 23 (2019) e00134forms of ALK2 [4,6]. All-trans retinoic acid (RA) agonists are also a con-
sideration, as they have been shown to inhibit chondrogenesis inmouse
models by reducing the level of Smad proteins and subsequently HO [4].
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